Related references
Note: Only part of the references are listed.Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
Ahmed M. Shaman et al.
CIRCULATION (2022)
GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue
Jonathan E. Campbell et al.
DIABETES (2022)
The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis
Jonathan M. Wilson et al.
DIABETES OBESITY & METABOLISM (2022)
An inter-organ neural circuit for appetite suppression
Tong Zhang et al.
CELL (2022)
Obesity-associated Blunted Subcutaneous Adipose Tissue Blood Flow After Meal Improves After Bariatric Surgery
Teemu Saari et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
Naveed Sattar et al.
NATURE MEDICINE (2022)
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
Amalia Gastaldelli et al.
LANCET DIABETES & ENDOCRINOLOGY (2022)
Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research
Xiaoyan Yang et al.
FRONTIERS IN NEUROLOGY (2022)
GLP-1 physiology informs the pharmacotherapy of obesity
Daniel J. Drucker
MOLECULAR METABOLISM (2022)
Glucagon-like Peptide-1 receptor Tie2+cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction
Brent A. McLean et al.
MOLECULAR METABOLISM (2022)
What's preventing us from curbing the obesity crisis?
[Anonymous]
LANCET DIABETES & ENDOCRINOLOGY (2022)
A brainstem circuit for nausea suppression
Chuchu Zhang et al.
CELL REPORTS (2022)
Glucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Activation
Katherine N. Cahil et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2022)
Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation
Chi Kin Wong et al.
CELL METABOLISM (2022)
GIP Affects Hepatic Fat and Brown Adipose Tissue Thermogenesis but Not White Adipose Tissue Transcriptome in Type 1 Diabetes
Sebastian Moller Nguyen Heimburger et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)
Genetic disruption of the Gipr in Apoe-/- mice promotes atherosclerosis
Gemma Pujadas et al.
MOLECULAR METABOLISM (2022)
Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue
Ricardo J. Samms et al.
MOLECULAR METABOLISM (2022)
Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet
Emmanuel Somm et al.
TRANSLATIONAL RESEARCH (2021)
A microbial metabolite remodels the gut-liver axis following bariatric surgery
Snehal N. Chaudhari et al.
CELL HOST & MICROBE (2021)
Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy
Chintan V. Dave et al.
CIRCULATION (2021)
Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes
Mark M. Smits et al.
DIABETES & METABOLISM (2021)
Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults
Elisabetta Patorno et al.
DIABETES CARE (2021)
The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study
Juraj Koska et al.
DIABETES CARE (2021)
Glucose-Dependent Insulinotropic Peptide in the High-Normal Range Is Associated With Increased Carotid Intima-Media Thickness
Amra Jujic et al.
DIABETES CARE (2021)
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
Brent A. McLean et al.
ENDOCRINE REVIEWS (2021)
The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
Qian Zhang et al.
CELL METABOLISM (2021)
DAla2-GIP-GLU-PAL Protects Against Cognitive Deficits and Pathology in APP/PS1 Mice by Inhibiting Neuroinflammation and Upregulating cAMP/PKA/CREB Signaling Pathways
Li Yuan et al.
JOURNAL OF ALZHEIMERS DISEASE (2021)
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells
K. El et al.
SCIENCE ADVANCES (2021)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Naveed Sattar et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial
Jacob K. Jensen et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Differential importance of endothelia and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide
Brent A. McLean et al.
JCI INSIGHT (2021)
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice
Hyo Shin Yoon et al.
NATURE MICROBIOLOGY (2021)
Effect of Liraglutide on Arterial Inflammation Assessed as [18F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
Rasmus S. Ripa et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2021)
Genetically Predicted Glucose-Dependent Insulinotropic Polypeptide (GIP) Levels and Cardiovascular Disease Risk Are Driven by Distinct Causal Variants in the GIPR Region
Nicholas Bowker et al.
DIABETES (2021)
GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models
Tito Borner et al.
DIABETES (2021)
Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling
Ville Karhunen et al.
DIABETOLOGIA (2021)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frias et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effect of liraglutide on expression of inflammatory genes in type 2 diabetes
Emilie H. Zobel et al.
SCIENTIFIC REPORTS (2021)
Glucose-Dependent Insulinotropic Polypeptide Suppresses Foam Cell Formation of Macrophages through Inhibition of the Cyclin-Dependent Kinase 5-CD36 Pathway
Michishige Terasaki et al.
BIOMEDICINES (2021)
Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors
David Z. I. Cherney et al.
MED (2021)
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson's disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The 'Exenatide-PD3' study
Nirosen Vijiaratnam et al.
BMJ OPEN (2021)
Acute Kidney Injury Associated With Semaglutide
David J. Leehey et al.
KIDNEY MEDICINE (2021)
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Ricardo J. Samms et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
The gut microbiota regulates hypothalamic inflammation and leptin sensitivity in Western diet-fed mice via a GLP-1R-dependent mechanism
Christina N. Heiss et al.
CELL REPORTS (2021)
GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys
Shu-Chen Lu et al.
CELL REPORTS MEDICINE (2021)
A genetic map of the mouse dorsal vagal complex and its role in obesity
Mette Q. Ludwig et al.
NATURE METABOLISM (2021)
Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction
Florian Kahles et al.
EUROPEAN HEART JOURNAL (2020)
Vasodilatory Actions of Glucagon-Like Peptide 1 Are Preserved in Skeletal and Cardiac Muscle Microvasculature but Not in Conduit Artery in Obese Humans With Vascular Insulin Resistance
Nasui Wang et al.
DIABETES CARE (2020)
A GLP-1/GIP/Gcg receptor triagonist improves memory behavior, as well as synaptic transmission, neuronal excitability and Ca2+ homeostasis in 3xTg-AD mice
Tian Li et al.
NEUROPHARMACOLOGY (2020)
GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats
Samantha M. Fortin et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics
Julia Ast et al.
NATURE COMMUNICATIONS (2020)
Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study
Bjorn Pasternak et al.
DIABETES CARE (2020)
Pharmacological antagonism of the incretin system protects against diet-induced obesity
Berit Svendsen et al.
MOLECULAR METABOLISM (2020)
The gut hormone receptor GIPR links energy availability to the control of hematopoiesis
Gemma Pujadas et al.
MOLECULAR METABOLISM (2020)
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design
Donna H. Ryan et al.
AMERICAN HEART JOURNAL (2020)
Discordance between GLP-1R gene and protein expression in mouse pancreatic islet cells
Sarah M. Gray et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
Tali Cukierman-Yaffe et al.
LANCET NEUROLOGY (2020)
Circadian GLP-1 Secretion in Mice Is Dependent on the Intestinal Microbiome for Maintenance of Diurnal Metabolic Homeostasis
Sarah E. Martchenko et al.
DIABETES (2020)
Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism
Elizabeth A. Killion et al.
NATURE COMMUNICATIONS (2020)
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
Laurie L. Baggio et al.
MOLECULAR METABOLISM (2020)
Liraglutide Improves the Kidney Function in a Murine Model of Chronic Kidney Disease
Maria E. Ougaard et al.
NEPHRON (2020)
Semaglutide lowers body weight in rodents via distributed neural pathways
Sanaz Gabery et al.
JCI INSIGHT (2020)
Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
Natasha C. Bergmann et al.
DIABETOLOGIA (2019)
Gut intraepithelial T cells calibrate metabolism and accelerate cardiovascular disease
Shun He et al.
NATURE (2019)
Persistently Elevated Glucagon-Like Peptide-1 Levels among Critically Ill Surgical Patients after Sepsis and Development of Chronic Critical Illness and Dismal Long-Term Outcomes
Scott C. Brakenridge et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2019)
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Gut-Proglucagon-Derived Peptides Are Essential for Regulating Glucose Homeostasis in Mice
Youngmi Song et al.
CELL METABOLISM (2019)
Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
Alice E. Adriaenssens et al.
CELL METABOLISM (2019)
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Helena W. Rodbard et al.
DIABETES CARE (2019)
Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition
Kentaro Kaneko et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Physiological roles of the GIP receptor in murine brown adipose tissue
Jacqueline L. Beaudry et al.
MOLECULAR METABOLISM (2019)
Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease
Kathleen T. Watson et al.
BEHAVIOURAL BRAIN RESEARCH (2019)
Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals
Laerke S. Gasbjerg et al.
DIABETES (2019)
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Piotr A. Mroz et al.
MOLECULAR METABOLISM (2019)
GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9
Fernanda Dana Mantelmacher et al.
NATURE METABOLISM (2019)
Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia
Mikkel B. Christensen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction
John R. Ussher et al.
CELL METABOLISM (2018)
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Daniel J. Drucker
CELL METABOLISM (2018)
Bilateral quinolinic acid-induced lipid peroxidation, decreased striatal monoamine levels and neurobehavioral deficits are ameliorated by GIP receptor agonist D-Ala2GIP in rat model of Huntington's disease
Mahip K. Verma et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE-/- mice by blocking monocyte/macrophage activation
Florian Kahles et al.
MOLECULAR METABOLISM (2018)
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
Elizabeth A. Killion et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Glucose-Dependent Insulinotropic Polypeptide Suppresses Peripheral Arterial Remodeling in Male Mice
Yusaku Mori et al.
ENDOCRINOLOGY (2018)
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways
Gunaj Rakipovski et al.
JACC-BASIC TO TRANSLATIONAL SCIENCE (2018)
Enteroendocrine K and L cells in healthy and type 2 diabetic individuals
Tina Jorsal et al.
DIABETOLOGIA (2018)
GLP-1 Receptor Expression Within the Human Heart
Laurie L. Baggio et al.
ENDOCRINOLOGY (2018)
The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice
Melissa A. Burmeister et al.
DIABETES (2017)
The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of gsp- somatotropinomas
D. Regazzo et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease
Ziyue Yuan et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2017)
D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation
Yanwei Li et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2017)
Discovery, characterization, and clinical development of the glucagon-like peptides
Daniel J. Drucker et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Glucose-Dependent Insulinotropic Polypeptide Receptor Deficiency Leads to Impaired Bone Marrow Hematopoiesis
Fernanda Dana Mantelmacher et al.
JOURNAL OF IMMUNOLOGY (2017)
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Dilan Athauda et al.
LANCET (2017)
Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion
Lorene J. Lebrun et al.
CELL REPORTS (2017)
The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor
Meena Asmar et al.
DIABETES (2017)
GLP-1 Levels Predict Mortality in Patients with Critical Illness as Well as End-Stage Renal Disease
Corinna Lebherz et al.
AMERICAN JOURNAL OF MEDICINE (2017)
Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response
Sravan K. Thondam et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2017)
The Cardiovascular Biology of Glucagon-like Peptide-1
Daniel J. Drucker
CELL METABOLISM (2016)
Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes
Asa Segerstolpe et al.
CELL METABOLISM (2016)
Suppressive Effects of Glucose-Dependent Insulinotropic Polypeptide on Cardiac Hypertrophy and Fibrosis in Angiotensin II-Infused Mouse Models
Munenori Hiromura et al.
CIRCULATION JOURNAL (2016)
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew James Armstrong et al.
LANCET (2016)
Increased GIP signaling induces adipose inflammation via a HIF-1α-dependent pathway and impairs insulin sensitivity in mice
Shu Chen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2015)
Glucose-dependent insulinotropic polypeptide directly induces glucose transport in rat skeletal muscle
Laelie A. Snook et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2015)
GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R
Bernardo Yusta et al.
DIABETES (2015)
GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial
Oezlem Goegebakan et al.
DIABETOLOGIA (2015)
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Xavier Pi-Sunyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Oxyntomodulin regulates resetting of the liver circadian clock by food
Dominic Landgraf et al.
ELIFE (2015)
Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes
Julie A. Lovshin et al.
DIABETES CARE (2015)
Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow
Elisa P. Jensen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans
Sharmila C. Subaran et al.
CLINICAL SCIENCE (2014)
Lipopolysaccharides-Mediated Increase in Glucose-Stimulated Insulin Secretion: Involvement of the GLP-1 Pathway
Anh Thoai Nguyen et al.
DIABETES (2014)
GLP-1 Secretion Is Increased by Inflammatory Stimuli in an IL-6-Dependent Manner, Leading to Hyperinsulinemia and Blood Glucose Lowering
Florian Kahles et al.
DIABETES (2014)
GLP-1 Agonism Stimulates Brown Adipose Tissue Thermogenesis and Browning Through Hypothalamic AMPK
Daniel Beiroa et al.
DIABETES (2014)
GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
Charles Pyke et al.
ENDOCRINOLOGY (2014)
Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
J. van Can et al.
INTERNATIONAL JOURNAL OF OBESITY (2014)
Glucose-dependent insulinotropic polypeptide has impaired effect on abdominal, subcutaneous adipose tissue metabolism in obese subjects
M. Asmar et al.
INTERNATIONAL JOURNAL OF OBESITY (2014)
Elimination and Degradation of Glucagon-like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide in Patients with End-Stage Renal Disease
Thomas Idorn et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients With Type 2 Diabetes
Mikkel B. Christensen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
A Functional Amino Acid Substitution in the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) Gene Is Associated With Lower Bone Mineral Density and Increased Fracture Risk
S. S. Torekov et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Long-Acting Glucose-Dependent Insulinotropic Polypeptide Ameliorates Obesity-Induced Adipose Tissue Inflammation
Chen Varol et al.
JOURNAL OF IMMUNOLOGY (2014)
The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential
Hiroki Fujita et al.
KIDNEY INTERNATIONAL (2014)
Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection
John R. Ussher et al.
MOLECULAR METABOLISM (2014)
The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty
Astrid Plamboeck et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2013)
Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
Jonathan E. Campbell et al.
CELL METABOLISM (2013)
A Glucagon-Like Peptide-1 Analog Reverses the Molecular Pathology and Cardiac Dysfunction of a Mouse Model of Obesity
Mohammad Hossein Noyan-Ashraf et al.
CIRCULATION (2013)
Link Between GIP and Osteopontin in Adipose Tissue and Insulin Resistance
Emma Ahlqvist et al.
DIABETES (2013)
GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE(-/-) Mice
Naim Panjwani et al.
ENDOCRINOLOGY (2013)
Exenatide and the treatment of patients with Parkinson's disease
Iciar Aviles-Olmos et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
THE INCRETIN ANALOGUE D-ALA2GIP REDUCES PLAQUE LOAD, ASTROGLIOSIS AND OXIDATIVE STRESS IN AN APP/PS1 MOUSE MODEL OF ALZHEIMER'S DISEASE
A. M. Duffy et al.
NEUROSCIENCE (2013)
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Brian Finan et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
James L. Trevaskis et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2012)
Gipr Is Essential for Adrenocortical Steroidogenesis, However, Corticosterone Deficiency Does Not Mediate the Favorable Metabolic Phenotype of Gipr-/- Mice
Holly E. Bates et al.
DIABETES (2012)
Glucagon-Like Peptide 1 Recruits Microvasculature and Increases Glucose Use in Muscle via a Nitric Oxide-Dependent Mechanism
Weidong Chai et al.
DIABETES (2012)
Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice
Emilie Faivre et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2012)
Exenatide Exerts a Potent Antiinflammatory Effect
Ajay Chaudhuri et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Glucose-Dependent Insulinotropic Polypeptide Prevents the Progression of Macrophage-Driven Atherosclerosis in Diabetic Apolipoprotein E-Null Mice
Yukinori Nogi et al.
PLOS ONE (2012)
GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis
Su-Jin Kim et al.
PLOS ONE (2012)
Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice
Timo Rieg et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2012)
Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
Michael A. Nauck et al.
DIABETES (2011)
Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
M. Nagashima et al.
DIABETOLOGIA (2011)
Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice
David W. Porter et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2011)
Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells
Helga Ellingsgaard et al.
NATURE MEDICINE (2011)
Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells
I. Hadjiyanni et al.
DIABETOLOGIA (2010)
Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
Lotte Bjerre Knudsen et al.
ENDOCRINOLOGY (2010)
GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene
Su-Jin Kim et al.
JOURNAL OF LIPID RESEARCH (2010)
GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
Mohammad Hossein Noyan-Ashraf et al.
DIABETES (2009)
Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
P. V. Hojberg et al.
DIABETOLOGIA (2009)
A novel GIP receptor splice variant influences GIP sensitivity of pancreatic beta-cells in obese mice
Norio Harada et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2008)
The murine glucagon-like peptide-1 receptor is essential for control of bone resorption
Chizumi Yamada et al.
ENDOCRINOLOGY (2008)
Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet
Matthew C. Althage et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain
Jenny Nyberg et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2007)
Effects of glucose-dependent insulinotropic peptide on osteoclast function
Qing Zhong et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2007)
Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure
Tanya Hansotia et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification
Lisa Getty-Kaushik et al.
OBESITY (2006)
Prohormone convertase 1/3 is essential for processing of the glucose-dependent insulinotropic polypeptide precursor
R Ugleholdt et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Glucose-dependent insulinotropic polypeptide is expressed in adult hippocampus and induces progenitor cell proliferation
J Nyberg et al.
JOURNAL OF NEUROSCIENCE (2005)
Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects
JJ Meier et al.
DIABETES (2004)
Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men
JP Gutzwiller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
International union of pharmacology.: XXXV.: The glucagon receptor family
KE Mayo et al.
PHARMACOLOGICAL REVIEWS (2003)
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
K Miyawaki et al.
NATURE MEDICINE (2002)
Share Paper
